The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation
Open accessAbstract
// Hyung Kwon Byeon 1 , Hwi Jung Na 1 , Yeon Ju Yang 1 , Sooah Ko 1 , Sun Och Yoon 2 , Minhee Ku 3, 4 , Jaemoon Yang 3, 5 , Jae Wook Kim 6 , Myung Jin Ban 6 , Ji-Hoon Kim 7 , Da Hee Kim 1 , Jung Min Kim 1 , Eun Chang Choi 1 , Chang-Hoon Kim 1, 8 , Joo-Heon Yoon 1, 8, 9 , Yoon Woo Koh 1, 8 1 Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea 2 Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea 3 Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea 4 Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea 5 YUHS-KRIBB Medical Convergence Research Institute, Seoul, Republic of Korea 6 Department of Otorhinolaryngology, Soonchunhyang University College of Medicine, Republic of Korea 7 Department of Otorhinolaryngology-Head and Neck Surgery, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea 8 The Airway Mucus Institute, Yonsei University College of Medicine, Seoul, Republic of Korea 9 Research Center for Human Natural Defense System, Yonsei University College of Medicine, Seoul, Republic of Korea Correspondence to: Yoon Woo Koh, email: ywkohent@yuhs.ac Keywords: thyroid cancer, molecular targeted therapy, drug resistance, BRAF mutation, epithelial-mesenchymal transition Received: September 23, 2016 Accepted: November 12, 2016 Published: November 21, 2016 ABSTRACT Previously, the authors have identified that c-Met mediates reactivation of the PI3K/AKT pathway following BRAF inhibitor treatment in BRAF (V600E) mutant anaplastic thyroid cancer, thereby contributing to the acquired drug resistance. Therefore dual inhibition of BRAF and c-Met led to sustained treatment response, thereby maximizing the specific anti-tumor effect of targeted therapy. The present study goes one step further and aims to investigate the effect of acquired resistance of BRAF inhibitor on epithelial-to-mesenchymal transition (EMT) in BRAF mutant thyroid cancer cells and the effect of dual inhibition from combinatorial therapy. Two thyroid cancer cell lines, 8505C and BCPAP were selected and treated with BRAF inhibitor, PLX4032 and its effect on EMT were examined and compared. Further investigation was carried out in orthotopic xenograft mouse models. Unlike BCPAP cells, the BRAF inhibitor resistant 8505C cells showed increased expressions of EMT related markers such as vimentin, β-catenin, and CD44. The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT. Similar results were confirmed in vivo . c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and further promotes tumor cell migration and invasion by upregulated EMT mechanism. Dual inhibition of BRAF and c-Met leads to reversal of EMT, suggesting a maximal therapeutic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Acquired resistance to BRAF inhibition has been linked to epithelial-to-mesenchymal transition (EMT) in melanoma and thyroid cancers [23,24].”
From Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer (2026) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Durante, C., Haddy, N., Baudin, É., Leboulleux, S., Hartl, D. M., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J., de Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,670
Papillary and Follicular Thyroid Carcinoma
Schlumberger, M. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380506 · Cited by 1,619
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,272
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,247
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,036
Mendez, M. G., Kojima, S.-I., & Goldman, R. D. (2010) · The FASEB Journal · doi:10.1096/fj.09-151639 · Cited by 933
A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition
Xu, W., Yang, Z., & Lü, N. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1016686 · Cited by 611
Flagged first, then by citations
Cited by
Sorted by citations
Diagnosis and Management of Anaplastic Thyroid Cancer
Chintakuntlawar, A. V., Foote, R. L., Kasperbauer, J. L., & Bible, K. C. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.10.010 · Cited by 93
Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
Moosavi, F., Giovannetti, E., Peters, G. J., & Firuzi, O. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103234 · Cited by 58
Wang, X., Jiang, W., Du, Y., Dongqi, Z., Zhang, J., Fang, C., Fang, Y., & Chen, Z.-S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100884 · Cited by 53
Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
Gheysen, L., Sven, S., & Journé, F. (2020) · Cells · doi:10.3390/cells9040830 · Cited by 44
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers
Hofmann, M.-C. C., Kunnimalaiyaan, M., Wang, J. R., Busaidy, N. L., Sherman, S. I., Lai, S. Y., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0129 · Cited by 39
Metadata
- Authors
- Byeon, H. K., Na, H. J., Yang, Y. J., Ko, S., Yoon, S. O., Ku, M., Yang, J., Kim, J. W., Ban, M. J., Kim, J.-H., Kim, D. H., Kim, J. M., Choi, E. C., Kim, C.-H., Yoon, J.-H., & Koh, Y. W.
- Affiliations
- Yonsei University (KR)
- Soonchunhyang University (KR)
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
- ORCID
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-11-21
- Volume
- 8
- Issue
- 1
- Pages
- 596-609
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5352181
- OpenAlex
- W2555358355
- Cited by
- 29
- References
- 47
- Citations by year
- 2026: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 1
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Research Foundation
- Yonsei University
- National Research Foundation of Korea (NRF-2016R1C1B2011211)
- Yonsei University College of Medicine
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- acquired drug resistance, BRAF V600E mutation, anaplastic thyroid carcinoma, epithelial-mesenchymal transition, c-Met, Akt activation, PI3K/Akt signaling, BRAF inhibitor resistance, targeted therapy, metastasis, lymph node metastasis, lung metastasis
- MeSH terms
- Vemurafenib, Animals, Disease Models, Animal, Humans, Indoles, Male, Mutation, Sulfonamides, Thyroid Neoplasms, Signal Transduction, Gene Expression, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt, Mice, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
